Physician profile
Sonia Sharma
NPI 1760656995
$4,556.79
in general payments reported to CMS, 2019-2025
32 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $213 · 2021: $13.17 · 2022: $312 · 2023: $649 · 2024: $1,243 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,030.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $747.49 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $558.13 | 2019-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $430.54 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.20 | 2019-2025 | Jardiance |
| Pfizer INC. | $287.31 | 2019-2025 | |
| Abbott Laboratories | $270.95 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $228.68 | 2019-2025 | Shingrix, Arexvy, Benlysta |
| Phathom Pharmaceuticals, INC. | $219.48 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $173.13 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Insulet Corporation | $169.21 | 2023-2025 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $144.45 | 2019-2023 | Trintellix |
| Abbvie INC. | $125.83 | 2023-2025 | Ubrelvy, Qulipta |
| Vivus LLC | $115.14 | 2019-2024 | Qsymia |
| Exact Sciences Corporation | $94.29 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $90.73 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $71.99 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.70 | 2024 | |
| Astellas Pharma US INC | $62.23 | 2023-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $60.72 | 2019-2024 | Xarelto |
| Sanofi Pasteur INC. | $58.09 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $47.80 | 2025 | Gemtesa |
| Hologic Sales and Service, LLC | $38.44 | 2019-2024 | Aptima, Thinprep 2000 Processor |
| Medtronic, INC. | $33.46 | 2022-2025 | Inceptiv |
| Allergan, INC. | $29.51 | 2019-2020 | |
| Sequel Med Tech, LLC | $23.84 | 2025 | Twiist |
| Nevro Corp. | $19.97 | 2023 | Senza |
| Ibsa Pharma INC. | $16.87 | 2019 | |
| Endo Pharmaceuticals INC. | $16.21 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.04 | 2020 | |
| Radius Health, INC. | $13.17 | 2021 | |
| Upsher-Smith Laboratories LLC | $12.65 | 2019 | |
| Amarin Pharma, INC. | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.